Why AFT Pharmaceuticals (ASX:AFP) Is on Investors’ Radar After Record FY2026 Results

Sonal Goyal

15 September 2026 03:08 AM AEST

Why AFT Pharmaceuticals (ASX:AFP) Is on Investors’ Radar After Record FY2026 Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

AFT Pharmaceuticals (ASX:AFP) has continued to expand its pharmaceutical operations across Australasia and international markets, with the company reporting record FY2026 financial results. The Business remains focused on product growth, Research and Development Investment and expanding its presence across overseas markets.

Latest Development

AFT Pharmaceuticals continued its corporate and operational activities during 2026, including Leadership changes and updates related to its annual Shareholder meeting.

The company appointed Stuart Houliston as chief financial officer in May 2026 and provided updates on its research and development activities and growth plans during the year.

Company Overview

AFT Pharmaceuticals develops, markets and distributes pharmaceutical products across prescription, over-the-counter and hospital channels.

The company operates across Australasia and international markets, using partnerships and licensing arrangements to expand the availability of its products.

AFT generates Revenue from product sales, royalties and licensing activities, with international expansion forming part of its growth strategy.

Financial and Operational Position

For FY2026, the year ended 31 March 2026, AFT Pharmaceuticals reported revenue of NZD 254.7 million, up 22% from the previous year.

Product sales and royalties increased during the period, while licensing income also grew. Operating profit increased to NZD 24.4 million, while EBITDA rose to NZD 28.8 million.

Net profit after tax was NZD 14.1 million for FY2026. The company also increased its Dividend distribution and continued investment in research and development activities.

Growth and Research Focus

AFT Pharmaceuticals continues to invest in research and development programs to support future product opportunities.

The company has highlighted growth opportunities across its existing portfolio and international markets, with expansion across Asia and other regions forming part of its broader strategy.

Future performance will depend on successful product development, commercial execution and market expansion.

What Investors May Watch Next

Investors may monitor progress against FY2027 guidance, including revenue growth, operating profit expectations and planned research and development investment.

The company’s half-year results for the period ending 30 September 2026 will provide further insight into trading performance, international growth and cost management.

Risks

Pharmaceutical development involves regulatory, commercial and market risks, with product approval timelines and customer adoption influencing future outcomes.

Higher research and development spending increases investment requirements, while changes in currency movements, healthcare regulation and competitive conditions may affect performance.

The company’s international operations also expose it to different market environments and regulatory frameworks.

Key Takeaway

AFT Pharmaceuticals enters the next phase of its growth strategy after reporting record FY2026 results, supported by revenue growth, higher profitability and continued investment in research. The company’s ability to deliver on FY2027 targets and expand its product portfolio will remain key areas to monitor.

FAQs

Q: What is the ASX ticker for AFT Pharmaceuticals Limited?

A: AFT Pharmaceuticals Limited trades under the ticker (ASX:AFP).

Q: Why is AFT Pharmaceuticals Limited in focus?

A: AFT Pharmaceuticals is in focus due to its FY2026 earnings performance, pharmaceutical portfolio and international expansion plans.

Q: What should investors monitor next for AFT Pharmaceuticals Limited?

A: Investors may monitor FY2027 guidance progress, research activities, financial results and future company updates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.